Infinity Pharmaceuticals (NASDAQ: INFI) is one of 196 public companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its competitors? We will compare Infinity Pharmaceuticals to similar companies based on the strength of its institutional ownership, profitability, risk, valuation, dividends, earnings and analyst recommendations.

Valuation and Earnings

This table compares Infinity Pharmaceuticals and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Infinity Pharmaceuticals N/A -$55.73 million -1.01
Infinity Pharmaceuticals Competitors $207.80 million -$2.20 million -0.04

Infinity Pharmaceuticals’ competitors have higher revenue and earnings than Infinity Pharmaceuticals. Infinity Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.


This table compares Infinity Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Infinity Pharmaceuticals N/A -88.08% -59.20%
Infinity Pharmaceuticals Competitors -3,997.03% -120.71% -44.63%

Analyst Recommendations

This is a breakdown of current ratings for Infinity Pharmaceuticals and its competitors, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Infinity Pharmaceuticals 0 1 0 0 2.00
Infinity Pharmaceuticals Competitors 463 2201 6081 117 2.66

As a group, “Biotechnology & Medical Research” companies have a potential upside of 2.53%. Given Infinity Pharmaceuticals’ competitors stronger consensus rating and higher possible upside, analysts plainly believe Infinity Pharmaceuticals has less favorable growth aspects than its competitors.

Risk and Volatility

Infinity Pharmaceuticals has a beta of 2.64, meaning that its stock price is 164% more volatile than the S&P 500. Comparatively, Infinity Pharmaceuticals’ competitors have a beta of 1.63, meaning that their average stock price is 63% more volatile than the S&P 500.

Insider & Institutional Ownership

67.5% of Infinity Pharmaceuticals shares are held by institutional investors. Comparatively, 47.0% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 6.8% of Infinity Pharmaceuticals shares are held by insiders. Comparatively, 13.8% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.


Infinity Pharmaceuticals competitors beat Infinity Pharmaceuticals on 8 of the 12 factors compared.

About Infinity Pharmaceuticals

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.

Receive News & Ratings for Infinity Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.